Pasireotide: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. The modules below summarise what published studies of pasireotide examined and reported. Nothing here is a protocol, a recommendation, or a promise of benefit.

Module 1 — What pasireotide is and how it has been studied

Definition and class

Pasireotide is a synthetic cyclohexapeptide somatostatin analogue. It belongs to the drug class usually described in the endocrine literature as somatostatin receptor ligands (SRLs), and it is frequently called a multireceptor-targeted or second-generation analogue because published pharmacology describes affinity across several somatostatin receptor subtypes rather than predominantly one. Trial documentation that selects patients by receptor expression makes this framing explicit: the design paper for the PAMSARC phase 2 trial enrolled tumours characterised as SSTR2/3/5-expressing before monthly pasireotide administration (PMID 40934647).

Origin and forms in the literature

Pasireotide was developed as a laboratory-designed analogue of native somatostatin, with the stated aim of broader receptor coverage than earlier analogues. Two administration formats appear repeatedly in published research. A short-acting subcutaneous format was used in the randomised perioperative trial of pasireotide 900 µg given subcutaneously twice daily for seven postoperative days after pancreatic resection (PMID 24849084). A long-acting intramuscular depot format, given at monthly intervals, was used in a multicenter study of long-acting pasireotide in somatostatin-resistant acromegaly (PMID 30051198), in a single-centre one-year real-world observation of pasireotide-LAR in resistant acromegaly (PMID 34498217), and in a phase III study of long-acting pasireotide in Cushing's disease (PMID 32385851).

Where the research sits

Limits of the evidence in Module 1

The verified literature summarised here describes formats and settings, not a complete pharmacological profile. Receptor-affinity numbers, manufacturing details and comparative potency rankings against other analogues are not established by the papers cited on this page, and no verified paper here characterises pasireotide outside the clinical and laboratory contexts listed above.

Module 2 — Mechanism as described in the literature

Receptor engagement

The mechanistic logic in published pasireotide research rests on somatostatin receptor binding. Investigators designing the PAMSARC trial selected synovial sarcoma and desmoplastic small round cell tumours that expressed SSTR2, SSTR3 and SSTR5, on the stated rationale that pasireotide engages those subtypes (PMID 40934647). In pituitary disease, the same reasoning is used to explain why some tumours that respond poorly to first-generation analogues were studied with pasireotide instead, as in the multicenter study of patients defined as somatostatin-resistant (PMID 30051198).

Downstream signalling

One laboratory study went further downstream: researchers working in an ACTH-secreting pituitary tumour cell line reported that protein kinase C delta mediated the effects of pasireotide in that model (PMID 37233978). That work describes an intracellular route by which receptor binding could translate into altered hormone output in corticotroph tumour cells, and it is a cell-line experiment rather than a human observation.

Effects on hormone axes and on glucose handling

Two mechanistic threads recur. First, suppression of pituitary hormone output: studies in acromegaly measured growth hormone and IGF-1 as the operative readouts (PMID 34498217), and studies in Cushing's disease measured cortisol-related endpoints alongside clinical signs (PMID 32385851). Second, effects on pancreatic islet hormones: an investigation of patients with Cushing's disease treated with pasireotide examined insulin sensitivity, insulin secretion and the adipokine profile, and the study reported changes in these metabolic parameters during treatment (PMID 29396758). The same biology is used in the opposite direction in a report of malignant insulinoma, where reduced insulin output was the therapeutic intention rather than an unwanted effect (PMID 26732164).

Limits of the evidence in Module 2

Mechanistic descriptions here are inferred from clinical endpoints and from a single cell-line experiment. No verified paper on this page maps pasireotide binding affinities quantitatively, and the PKC-delta pathway reported in one corticotroph cell line has not been shown on this page to operate in human tumours, in other tissues, or in healthy physiology.

Module 3 — Reported outcomes by study

Acromegaly

Acromegaly is the most densely studied indication in the verified set. A 2025 report examined pasireotide as first-line medical therapy in selected patients with acromegaly and described biochemical outcomes in that selected group (PMID 40216609). A multicenter study of long-acting pasireotide in patients classified as somatostatin-resistant reported efficacy and safety outcomes in that resistant population (PMID 30051198), and a single-centre one-year real-world observation reported outcomes with pasireotide-LAR in resistant acromegaly under routine-care conditions rather than trial conditions (PMID 34498217). A 2025 European Journal of Endocrinology analysis addressed a different endpoint and reported long-term antitumour effects of pasireotide in acromegaly, that is, tumour-size behaviour over extended follow-up rather than hormone levels alone (PMID 40974037). A further report examined pasireotide as a potential treatment option for acromegaly associated with McCune-Albright syndrome, a rare genetic context (PMID 38128124).

Cushing's disease

In Cushing's disease, a phase III study of long-acting pasireotide reported improvements in clinical signs and in quality-of-life measures among the patients studied (PMID 32385851). A separate investigation focused on metabolic physiology and reported on insulin sensitivity, insulin secretion and adipokine concentrations in patients with Cushing's disease treated with pasireotide (PMID 29396758).

Surgical and oncological settings

Outside pituitary disease, a randomised trial published in 2014 gave pasireotide 900 µg subcutaneously twice daily for seven perioperative days to patients undergoing pancreatic resection and reported a lower rate of the composite primary endpoint of clinically significant postoperative pancreatic fistula, leak or abscess in the pasireotide group compared with placebo (PMID 24849084). In oncology, a case report described pasireotide use in malignant insulinoma with attention to glycaemic outcomes (PMID 26732164), and the PAMSARC publication set out the rationale and design of a multicenter phase 2 trial of monthly deep intramuscular pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumour, meaning that its outcomes were not yet reported in that paper (PMID 40934647).

Veterinary and laboratory models

A veterinary study investigated pasireotide for the medical management of feline hypersomatotropism and reported reductions in serum IGF-1 together with changes in insulin requirements in the cats studied (PMID 25945588). At the bench, researchers reported that pasireotide's effects in an ACTH-secreting pituitary tumour cell line were mediated by protein kinase C delta (PMID 37233978).

Limits of the evidence in Module 3

Several of these reports are small, single-centre, uncontrolled, or descriptions of individual patients, and one is a trial design without results. Populations were highly selected — resistant acromegaly, confirmed receptor expression, patients already under specialist endocrine care — so reported outcomes describe those groups only. None of these papers supports a general claim about pasireotide in people without the conditions studied, and outcome measures differed enough between studies that direct comparison is not possible from the material cited here.

Module 4 — Pasireotide Side Effects: What Studies Report

Glucose metabolism

The most consistent safety theme in the verified literature concerns glucose handling. The multicenter study of long-acting pasireotide in somatostatin-resistant acromegaly reported safety alongside efficacy, with disturbance of glucose metabolism among the tolerability issues described in that resistant population (PMID 30051198). The one-year real-world observation of pasireotide-LAR in resistant acromegaly likewise reported glycaemic changes during routine treatment and monitoring (PMID 34498217). A mechanistically oriented study in Cushing's disease reported altered insulin secretion and insulin sensitivity together with shifts in the adipokine profile in patients treated with pasireotide, which is the physiological basis usually offered for the hyperglycaemia signal (PMID 29396758). The same pharmacological property was the intended effect in a report of malignant insulinoma, where pasireotide was used in a patient whose problem was excessive insulin secretion (PMID 26732164).

Tolerability in controlled and long-term settings

The randomised perioperative trial of pasireotide 900 µg subcutaneously twice daily for seven days after pancreatic surgery collected adverse events alongside its surgical endpoint (PMID 24849084). In Cushing's disease, the phase III analysis of long-acting pasireotide reported clinical-sign and quality-of-life outcomes within a trial that also monitored safety in the enrolled population (PMID 32385851), and the long-term acromegaly analysis followed patients over extended treatment periods while reporting antitumour endpoints (PMID 40974037). In animals, the feline hypersomatotropism study monitored treated cats clinically and biochemically while reporting IGF-1 and insulin-requirement changes (PMID 25945588).

Limits of the evidence in Module 4

Adverse-event reporting in these papers reflects supervised clinical settings with laboratory monitoring, short-to-medium follow-up and small numbers. Rare events, interactions with other medicines, and effects in people without the studied conditions are not characterised by the verified papers cited here. A signal reported in one population does not establish frequency or severity in another, and none of this material describes what happens when pasireotide is used without medical supervision.

Module 5 — Pharmacokinetics where data exist

The verified papers on this page are clinical outcome studies, a trial design paper, a cell-line experiment and a veterinary study; none of them is a dedicated human pharmacokinetic investigation. What can be stated factually is limited to the administration schedules the studies used, which reflect the pharmacokinetic behaviour of the two formats.

• Short-acting subcutaneous format: the randomised perioperative trial used twice-daily subcutaneous administration of 900 µg over seven days, a schedule consistent with a short dosing interval (PMID 24849084).
• Long-acting intramuscular depot: the PAMSARC trial design specified monthly deep intramuscular injection as maintenance treatment (PMID 40934647), and acromegaly and Cushing's disease studies used long-acting pasireotide on monthly intervals (PMID 30051198, PMID 32385851).
• Duration of exposure: real-world follow-up over one year (PMID 34498217) and long-term follow-up for antitumour endpoints (PMID 40974037) indicate that repeated monthly administration has been studied over extended periods in acromegaly.

Limits of the evidence in Module 5

No absorption, distribution, metabolism, elimination, half-life, bioavailability or renal/hepatic adjustment data can be drawn from the verified papers listed here. Dosing intervals used in trials are not a substitute for pharmacokinetic parameters, and this page does not supply them.

Module 6 — Regulatory status, stated factually

Approved medicines

Pasireotide exists as a prescription medicine: short-acting subcutaneous and long-acting intramuscular pasireotide products have marketing authorisations in the United States and European Union for pituitary indications, and the clinical studies summarised above were conducted in that regulated context, including a phase III programme in Cushing's disease (PMID 32385851) and registered trial activity in oncology (PMID 40934647). Approved-product labelling, not this page, is the authoritative source for indications, contraindications and monitoring requirements.

Research-use-only material

Peptides sold with "research use only" (RUO) labelling are supplied for laboratory work. RUO material is not an approved medicine, is not reviewed for human use, and carries no assurance of identity, purity or sterility equivalent to a pharmaceutical product. The distinction matters when reading literature: studies such as the cell-line work on protein kinase C delta used laboratory material in vitro (PMID 37233978), whereas human studies used pharmaceutical product.

Compounding

In the United States, compounding of drug products is governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Those provisions restrict compounding of preparations that are essentially copies of commercially available approved drugs, and eligibility of a given substance depends on lists and determinations maintained by the FDA. Veterinary use follows a separate framework; the feline hypersomatotropism study was conducted in veterinary practice (PMID 25945588).

This section describes published regulatory frameworks for general education and is not legal advice.

Limits of the evidence in Module 6

Regulatory status changes and differs by country, and the verified papers on this page do not adjudicate legality. Approval in one jurisdiction for one indication says nothing about other indications or other countries.

What the studies did not test

Read together, the verified literature on pasireotide leaves large gaps. The studies cited here did not test use in healthy people, in athletic or cosmetic contexts, or for weight management, and they did not examine unsupervised use without laboratory monitoring of glucose and pituitary hormones. They did not establish comparative superiority over other somatostatin analogues, did not test combinations with other peptides or hormones, and — in the case of the sarcoma trial — had not yet reported outcomes at all (PMID 40934647). Several reports involved single patients or rare syndromes, such as McCune-Albright-associated acromegaly (PMID 38128124) and malignant insulinoma (PMID 26732164), where generalisation is not possible. Pregnancy, paediatric populations and long-term outcomes beyond the follow-up periods studied are not addressed by the papers cited on this page. Readers interested in how pasireotide behaved in a specific population should go to the primary publications below and read what researchers actually measured.

References

• Pasireotide as first line medical therapy for selected patients with acromegaly (Pituitary, 2025)
• Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study (Endocrine, 2018)
• Pasireotide for postoperative pancreatic fistula (The New England Journal of Medicine, 2014)
• Pasireotide for malignant insulinoma (Hormones, 2016)
• Rationale and design of the PAMSARC multicenter phase 2 trial in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor (Cancer Treatment and Research Communications, 2025)
• Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide (Journal of Endocrinological Investigation, 2018)
• Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study (Journal of Endocrinological Investigation, 2020)
• Pasireotide: potential treatment option for McCune-Albright-associated acromegaly (European Journal of Endocrinology, 2024)
• Pasireotide for the Medical Management of Feline Hypersomatotropism (Journal of Veterinary Internal Medicine, 2015)
• Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line (Journal of Endocrinological Investigation, 2023)
• Long-term antitumour effects of pasireotide in acromegaly (European Journal of Endocrinology, 2025)
• Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation (Pituitary, 2022)